Explain the Controversy About the New Sublingual Sufentanil (Dsuvia)

You'll hear about a new sublingual sufentanil tablet (Dsuvia, deh-SOO-vee-uh) for acute pain management.

It was initially developed for battlefield use.

But FDA approval of this potent opioid during the opioid epidemic...with its easy-to-administer dosage form...is stirring up concerns.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

  • 12 issues every year — what you need to know and do, right now
  • Quick, practical reference charts and tools
  • Comprehensive CE library to meet license renewal and state requirements
  • Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
  • Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote